Marco Ruella

This inventor holds 16 USPTO granted patents and 21 published patent applications, plus 1 CIPO patent and 7 EPO patents, primarily in Chimeric Antigen Receptors. Top assignees: University of Pennsylvania, Novartis Ag, Abclon Inc.. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Marco Ruella. Retrieved from https://idiyas.com/inventor/marco-ruella

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 16 (Patent Applications = 21)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 10)

EPO Patents = 7 (Patent Applications = 22)

Average Co-Inventor Count = 10.9

ph-index = 5

Forward Citations = 160(Granted Patents)

Location History:

Philadelphia, PA (US) (2017 - 2019)
Ardmore, PA (US) (2020 - 2024)

Company Filing History:

16 out of 2,663

University of Pennsylvania

where one patent can have more than one assignee

Years Active: 2017-2026

Loading Chart...

Areas of Expertise:

Chimeric Antigen Receptor

CD20

BCMA

T Cell Lymphomas

Leukemias

Nucleic Acid Molecules

Combination Therapies

Anti-CD30

Humanized Therapies

CD123

Therapeutic Antibodies

Immune Effector Cells

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12668640 - ANTI-CD30 ANTIBODY AND CHIMERIC ANTIGEN RECEPTOR COMPRISING THEREOF (2026-06-30),

2. 12344657 - CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell (2025-07-01),

3. 12227588 - Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemias (2025-02-18),

4. 12214037 - Treatment of cancer using humanized anti-BCMA chimeric antigen receptor (2025-02-04),

5. RE49847 - Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain (2024-02-27),

6. 11872249 - Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain (2024-01-16),

7. 11673964 - Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemias (2023-06-13),

8. 11591404 - Treatment of cancer using a CD123 chimeric antigen receptor (2023-02-28),

9. 11149076 - CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell (2021-10-19),

10. 11084880 - Anti-BCMA chimeric antigen receptor (2021-08-10),

11. 11026976 - Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain (2021-06-08),

12. 10703819 - Treatment of cancer using a CD123 chimeric antigen receptor (2020-07-07),

13. 10357514 - Treatment of cancer using anti-CD19 Chimeric Antigen Receptor (2019-07-23),

14. 10253086 - CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell (2019-04-09),

15. 10174095 - Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor (2019-01-08),

Title: Marco Ruella: Innovator in Chimeric Antigen Receptor Therapies

Introduction

Marco Ruella is a prominent inventor based in Ardmore, PA (US), known for his significant contributions to the field of immunotherapy. He holds a total of 16 patents, focusing on innovative therapies that target specific antigens in the treatment of various diseases.

Latest Patents

Among his latest patents are groundbreaking therapies involving CD20, CD22, and combination therapies utilizing a CD19 chimeric antigen receptor (CAR)-expressing cell. These inventions provide compositions and methods for treating diseases associated with the expression of CD19. The approach includes administering a recombinant T cell comprising the CD19 CAR, in combination with one or more B-cell inhibitors. Additionally, his patents feature novel antigen binding domains and CAR molecules directed to CD20 and CD22, which can be used as monotherapies or in combination therapies. Another notable invention includes the use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemias, showcasing his commitment to advancing cancer treatment.

Career Highlights

Marco Ruella has worked with esteemed organizations such as the University of Pennsylvania and Novartis AG. His work in these institutions has allowed him to develop and refine his innovative therapies, contributing to the advancement of medical science.

Collaborations

Throughout his career, Marco has collaborated with notable colleagues, including Jennifer Brogdon and Saar Gill. These partnerships have played a crucial role in the development of his patented technologies.

Conclusion

Marco Ruella's contributions to the field of immunotherapy through his innovative patents and collaborations highlight his dedication to improving treatment options for patients. His work continues to influence the landscape of medical research and therapy development.

Profile summary based on public USPTO records.